MANGOCEUTICALS INC
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
MGRX$0.20+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| For the Year Ended · For the Year Ended | ||||
|---|---|---|---|---|
| December 31, 2023 · December 31, 2022 | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net loss | $(9,212,417) | $(1,998,055) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | 24,889 | 3,863 | ||
| Issuance of common stock for services | 1,530,651 | 540,065 | ||
| Imputed interest expense | - | 6,473 | ||
| Other income | (6,473) | - | ||
| Options vested for stock-based compensation | 624,463 | 234,088 | ||
| Warrants for service cancelled | - | (151,821) | ||
| (Increase) decrease in operating assets: | ||||
| Rent Deposits | - | (16,942) | ||
| Inventory | (18,501) | - | ||
| Prepaid expenses – related party | (49,208) | (11,745) | ||
| Operating lease right of use asset | 54,979 | (174,241) | ||
| (Decrease) increase in operating liabilities: | ||||
| Accounts payable and accrued liabilities | 107,090 | 33,675 | ||
| Operating lease right of use liabilities | (56,726) | 185,405 | ||
| Payroll tax liabilities | 3,878 | 2,717 | ||
| NET CASH USED IN OPERATING ACTIVITIES | (6,997,375) | (1,346,518) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Purchases of property and equipment | (3,519) | (43,102) | ||
| NET CASH USED IN INVESTING ACTIVITIES | (3,519) | (43,102) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds from borrowings on notes payable to related parties | - | 75,000 | ||
| Repayment on notes payable | (78,260) | - | ||
| Repayment on notes payable - related parties | (89,200) | (25,070) | ||
| Proceeds from exercise of warrants | 1,024,500 | - | ||
| Proceeds from sales of common stock for cash | 6,200,000 | 2,000,000 | ||
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 7,057,040 | 2,049,930 | ||
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 56,146 | 660,310 | ||
| CASH AND CASH EQUIVALENTS: | ||||
| Beginning of year | 682,860 | 22,550 | ||
| End of year | $739,006 | $682,860 | ||
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for income taxes | $ | - | $ | - |
| Cash paid for interest | $ | - | $ | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.